Regeneron expects $83 million IPR&D charge in third quarter 2025 results
NegativeFinancial Markets

Regeneron Pharmaceuticals has announced that it anticipates an $83 million charge related to its in-process research and development (IPR&D) for the third quarter of 2025. This significant financial adjustment raises concerns among investors about the company's ongoing projects and their potential impact on future earnings. Understanding these charges is crucial as they can affect the company's stock performance and investor confidence.
— Curated by the World Pulse Now AI Editorial System